Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FYN | P06241 | 17/20 | 0.61 |
| ▸ | PIM1 | P11309 | 1/20 | 0.51 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.50 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.49 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.49 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1053021 | 0.88 | FYN (0.68) | FYNPIK3CGNTRK1NTRK3NTRK2 | |
| SCHEMBL24828752 | 0.87 | FYN (0.61) | FYNPIM1PIK3CGNTRK1NTRK3 | |
| SCHEMBL23683388 | 0.85 | FYN (0.68) | FYNPIM1PIK3CG | |
| SCHEMBL23683338 | 0.82 | FYN (0.76) | FYNPIK3CGNTRK1NTRK3NTRK2 | |
| SCHEMBL1054612 | 0.81 | FYN (0.78) | FYNPIK3CGNTRK1NTRK3NTRK2 | |
| SCHEMBL2946495 | 0.79 | FYN (0.64) | FYNPIM1PIK3CGNTRK1NTRK3 | |
| SCHEMBL13234355 | 0.78 | MKNK1 (0.62) | FYNNTRK1NTRK3NTRK2 | |
| SCHEMBL1052973 | 0.76 | FYN (1.00) | FYNPIM1PIK3CG | |
| SCHEMBL30521897 | 0.76 | FYN (1.00) | FYN | |
| SCHEMBL18613318 | 0.76 | FYN (1.00) | FYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11542251-B2 | IRAK degraders and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-01-03 | — | — | US | disclosed |
| US-20210230144-A1 | IRAK DEGRADERS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11542251-B2 | IRAK degraders and uses thereof | IRAK2, IRAK1, IRAK4 | FYN 1032/4885PIM1 440/4885PIK3CG 1134/4885 |
| US-20210230144-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK1, IRAK4 | FYN 1032/4885PIM1 440/4885PIK3CG 1134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.